Class II Transactivator: Mastering the Art of Major Histocompatibility Complex Expression

REFERENCES

• Accolla, R. S., Jotterand-Bellomo, M., Scarpellino, L., Maffei, A., Carra, G., and Guardiola, J.. 1986. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J. Exp. Med. 164:369–374
   PubMed Web of Science ®Google Scholar
• Aisen, P. S.. 1996. Inflammation and Alzheimer disease. Mol. Chem. Neuropathol. 28:83–88
   PubMedGoogle Scholar
• Armstrong, T. D., Clements, V. K., Martin, B. K., Ting, J. P. Y., and Ostrand-Rosenberg, S.. 1997. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 94:6886–6891
   PubMed Web of Science ®Google Scholar
• Arnold, H. H., and Braun, T.. 1996. Targeted inactivation of myogenic factor genes reveals their role during mouse myogenesis: a review. Int. J. Dev. Biol. 40:345–353
   PubMedGoogle Scholar
• Balducci-Silano, P. L., Suzuki, K., Ohta, M., Saito, J., Ohmori, M., Montani, V., Napolitano, G., Shong, M., Taniguchi, S. I., Pietrarelli, M., Lavaroni, S., Mori, A., Singer, D. S., and Kohn, L. D.. 1998. Regulation of major histocompatibility (MHC) class II human leukocyte antigen-DR alpha gene expression in thyrocytes by single strand binding protein-1, a transcription factor that also regulates thyrotropin receptor and MHC class I gene expression. Endocrinology 139:2300–2313
   PubMedGoogle Scholar
• Baskar, S., Clements, V. K., Glimcher, L. H., Nabavi, N., and Ostrand-Rosenberg, S.. 1996. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J. Immunol. 156:3821–3827
   PubMed Web of Science ®Google Scholar
• Benichou, B., and Strominger, J. L.. 1991. Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis. Proc. Natl. Acad. Sci. USA 88:4285–4288
   PubMedGoogle Scholar
• Beutler, A. S., Banck, M. S., Wedekind, D., and Hedrich, H. J.. 1999. Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Hum. Gene Ther. 10:95–101
   PubMed Web of Science ®Google Scholar
• Bontron, S., Ucla, C., Mach, B., and Steimle, V.. 1997. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy. Mol. Cell. Biol. 17:4249–4258
   PubMedGoogle Scholar
• Boss, J. M.. 1997. Regulation of transcription of MHC class II genes. Curr. Opin. Immunol. 9:107–113
   PubMedGoogle Scholar
• Bradley, M. B., Fernandez, J. M., Ungers, G., Diaz-Barrientos, T., Steimle, V., Mach, B., O'Reilly, R., and Lee, J. S.. 1997. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA. J. Immunol. 159:1086–1095
   PubMedGoogle Scholar
• Brown, A. M., Linhoff, M. W., Stein, B., Wright, K. L., Baldwin, A. S. J., Basta, P. V., and Ting, J. P.. 1994. Function of NF-κB/Rel binding sites in the major histocompatibility complex class II invariant chain promoter is dependent on cell-specific binding of different NF-κB/Rel subunits. Mol. Cell. Biol. 14:2926–2935
   PubMedGoogle Scholar
• Brown, A. M., Wright, K. L., and Ting, J. P.. 1993. Human major histocompatibility complex class II-associated invariant chain gene promoter. Functional analysis and in vivo protein/DNA interactions of constitutive and IFN-gamma-induced expression. J. Biol. Chem. 268:26328–26333
   PubMedGoogle Scholar
• Brown, J. A., Rogers, E. M., and Boss, J. M.. 1998. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element. Nucleic Acids Res. 26:4128–4136
   PubMedGoogle Scholar
• Buchanan, S. G., and Gay, N. J.. 1996. Structural and functional diversity in the leucine-rich repeat family of proteins. Prog. Biophys. Mol. Biol. 65:1–44
   PubMedGoogle Scholar
• Calvert, I., Peng, Z. Q., Kung, H. F., Raziuddin. 1991. Cloning and characterization of a novel sequence-specific DNA-binding protein recognizing the negative regulatory element (NRE) region of the HIV-1 long terminal repeat. Gene 101:171–176
   PubMedGoogle Scholar
• Chang, C.-H., Guerder, S., Hong, S.-C., van Ewijk, W., and Flavell, R. A.. 1996. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4:167–178
   PubMed Web of Science ®Google Scholar
• Chang, C. H., and Flavell, R. A.. 1995. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J. Exp. Med. 181:765–767
   PubMed Web of Science ®Google Scholar
• Chang, C. H., Fontes, J. D., Peterlin, M., and Flavell, R. A.. 1994. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J. Exp. Med. 180:1367–1374
   PubMedGoogle Scholar
• Chang, C. H., Hong, S. C., Hughes, C. C., Janeway, C. A.Jr., and Flavell, R. A.. 1995. CIITA activates the expression of MHC class II genes in mouse T cells. Int. Immunol. 7:1515–1518
   PubMedGoogle Scholar
• Chapman, H. A.. 1998. Endosomal proteolysis and MHC class II function. Curr. Opin. Immunol. 10:93–102
   PubMed Web of Science ®Google Scholar
• Chin, K.-C., Li, G. X., and Ting, J. P.-Y.. 1997. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal CIITA deletion mutants. J. Immunol. 159:2789–2794
   PubMedGoogle Scholar
• Chin, K.-C., Mao, C., Skinner, C., Riley, J. L., Wright, K. L., Moreno, C. S., Stark, G. R., Boss, J. M., and Ting, J. P.-Y.. 1994. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity 1:687–697
   PubMedGoogle Scholar
• Chin, K. C., Li, G. G., and Ting, J. P.. 1997. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. Proc. Natl. Acad. Sci. USA 94:2501–2506
   PubMedGoogle Scholar
• Clements, V. K., Baskar, S., Armstrong, T. D., and Ostrand-Rosenberg, S.. 1992. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J. Immunol. 149:2391–2396
   PubMed Web of Science ®Google Scholar
• Cogswell, J. P., Austin, J., and Ting, J. P.. 1991. The W element is a positive regulator of HLA-DRA transcription in various DR+ cell types. J. Immunol. 146:1361–1367
   PubMedGoogle Scholar
• Collawn, J. F., and Benveniste, E. N.. 1999. Regulation of MHC class II expression in the central nervous system. Microbes Infect. 1:893–902
   PubMedGoogle Scholar
• Collinge, M., Pardi, R., and Bender, J. R.. 1998. Class II transactivator-independent endothelial cell MHC class II gene activation induced by lymphocyte adhesion. J. Immunol. 161:1589–1593
   PubMedGoogle Scholar
• Cressman, D. E., Chin, K.-C., Taxman, D. J., and Ting, J. P.-Y.. 1999. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity 10:163–171
   PubMed Web of Science ®Google Scholar
• de Preval, C., Lisowska-Grospierre, B., Loche, M., Griscelli, C., and Mach, B.. 1985. A trans-acting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes. Nature 318:291
   PubMedGoogle Scholar
• Dong, Y., Rohn, W. M., and Benveniste, E. N.. 1999. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes. J. Immunol. 162:4731–4739
   PubMedGoogle Scholar
• Douhan, J., Lieberson, R., Knoll, J. H., Zhou, H., and Glimcher, L. H.. 1997. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator. J. Exp. Med. 185:1885–1895
   PubMed Web of Science ®Google Scholar
• Durand, B., Sperisen, P., Emery, P., Barras, E., Zufferey, M., Mach, B., and Reith, W.. 1997. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16:1045–1055
   PubMedGoogle Scholar
• Erickson, F. L., Dinesh-Kumar, S. P., Holzberg, S., Ustach, C. V., Dutton, M., Handley, V., Corr, C., and Baker, B. J.. 1999. Interactions between tobacco mosaic virus and the tobacco N gene. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:653–658
   PubMedGoogle Scholar
• Fontes, J. D., Jabrane-Ferrat, N., Toth, C. R., and Peterlin, B. M.. 1996. Binding and cooperative interactions between two B cell-specific transcriptional coactivators. J. Exp. Med. 183:2517–2521
   PubMedGoogle Scholar
• Fontes, J. D., Jiang, B., and Peterlin, B. M.. 1997. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res. 25:2522–2528
   PubMed Web of Science ®Google Scholar
• Fontes, J. D., Kanazawa, S., Jean, D., and Peterlin, B. M.. 1999. Interactions between class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol. Cell. Biol. 19:941–947
   PubMedGoogle Scholar
• Fontes, J. D., Kanazawa, S., Nekrep, N., and Peterlin, B. M.. 1999. The class II transactivator CIITA is a transcriptional integrator. Microbes Infect. 1:863–869
   PubMedGoogle Scholar
• Ghosh, N., Piskurich, J. F., Wright, G., Hassani, K., Ting, J. P., and Wright, K. L.. 1999. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J. Biol. Chem. 274:32342–32350
   PubMedGoogle Scholar
• Gobin, S. J., and van den Elsen, P. J.. 1999. The regulation of HLA class I expression: is HLA-G the odd one out? Semin. Cancer Biol. 9:55–59
   PubMed Web of Science ®Google Scholar
• Gobin, S. J. P., Peijnenburg, A., Keijsers, V., and van den Elsen, P. J.. 1997. Site alpha is crucial for two routes of IFN-gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity 6:601–611
   PubMed Web of Science ®Google Scholar
• Gourley, T., Roys, S., Lukacs, N. W., Kunkel, S. L., Flavell, R. A., and Chang, C. H.. 1999. A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production. Immunity 10:377–386
   PubMedGoogle Scholar
• Han, Y., Zhou, Z. H., and Ransohoff, R. M.. 1999. TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA. J. Immunol. 163:1435–1440
   PubMedGoogle Scholar
• Harton, J. A., Cressman, D. E., Chin, K. C., Der, C. J., and Ting, J. P.. 1999. GTP binding by class II transactivator: role in nuclear import. Science 285:1402–1405
   PubMedGoogle Scholar
• Hillig, R. C., Renault, L., Vetter, I. R., Drell IV, T., Wittinghofer, A., and Becker, J.. 1999. The crystal structure of rna1p: a new fold for a GTPase-activating protein. Mol. Cell 3:781–791
   PubMed Web of Science ®Google Scholar
• Hume, C. R., and Lee, J. S.. 1989. Congenital immunodeficiencies associated with absence of HLA class II antigens on lymphocytes results from distinct mutations in trans-acting factors. Hum. Immunol. 26:288–309
   PubMedGoogle Scholar
• Inohara, N., Koseki, T., del Peso, L., Hu, Y., Yee, C., Chen, S., Carrio, R., Merino, J., Liu, D., Ni, J., and Nunez, G.. 1999. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J. Biol. Chem. 274:14560–14567
   PubMed Web of Science ®Google Scholar
• Itoh-Lindstrom, Y., Piskurich, J. F., Felix, N. J., Wang, Y., Brickey, W. J., Platt, J. L., Koller, B. H., and Ting, J. P.. 1999. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain. J. Immunol. 163:2425–2431
   PubMedGoogle Scholar
• Jabrane-Ferrat, N., Fontes, J. D., Boss, J. M., and Peterlin, B. M.. 1996. Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions. Mol. Cell. Biol. 16:4683–4690
   PubMedGoogle Scholar
• Kanazawa, S., Okamoto, T., and Peterlin, B. M.. 2000. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12:61–70
   PubMedGoogle Scholar
• Kern, I., Steimle, V., Siegrist, C. A., and Mach, B.. 1995. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes. Int. Immunol. 7:1295–1299
   PubMedGoogle Scholar
• Kobari, F., Sato, K., Shum, B. P., Tochinai, S., Katagiri, M., Ishibashi, T., Du Pasquier, L., Flajnik, M. F., and Kasahara, M.. 1995. Exon-intron organization of Xenopus MHC class II beta chain genes. Immunogen 42:376–385
   PubMedGoogle Scholar
• Kobe, B., and Deisenhofer, J.. 1993. Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature 366:751–756
   PubMed Web of Science ®Google Scholar
• Kovats, S., Main, E. K., Librach, C., Stubblebine, M., Fisher, S. J., and DeMars, R.. 1990. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248:220–223
   PubMed Web of Science ®Google Scholar
• Kretsovali, A., Agalioti, T., Spilianakis, C., Tzortzakaki, E., Merika, M., and Papamatheakis, J.. 1998. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with class II transactivator. Mol. Cell. Biol. 18:6777–6783
   PubMed Web of Science ®Google Scholar
• Laufer, T. M., von Herrath, M. G., Grusby, M. J., Oldstone, M. B., and Glimcher, L. H.. 1993. Autoimmune diabetes can be induced in transgenic major histocompatibility complex class II-deficient mice. J. Exp. Med. 178:589–596
   PubMed Web of Science ®Google Scholar
• Le Bouteiller, P., Solier, C., Proll, J., Aguerre-Girr, M., Fournel, S., and Lenfant, F.. 1999. Placental HLA-G protein expression in vivo: where and what for? Hum. Reprod. Update 5:223–233
   PubMed Web of Science ®Google Scholar
• Lee, Y. J., Han, Y., Lu, H. T., Nguyen, V., Qin, H., Howe, P. H., Hocevar, B. A., Boss, J. M., Ransohoff, R. M., and Benveniste, E. N.. 1997. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J. Immunol. 158:2065–2075
   PubMed Web of Science ®Google Scholar
• Lefebvre, S., Moreau, P., Dausset, J., Carosella, E. D., and Paul, P.. 1999. Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA. Placenta 20:293–301
   PubMedGoogle Scholar
• Lennon, A. M., Ottone, C., Rigaud, G., Deaven, L. L., Longmire, J., Fellous, M., Bono, R., and Alcaide-Loridan, C.. 1997. Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogen 45:266–273
   PubMedGoogle Scholar
• Le Roy, E., Muhlethaler-Mottet, A., Davrinche, C., Mach, B., and Davignon, J. L.. 1999. Escape of human cytomegalovirus from HLA-DR-restricted CD4+ T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression. J. Virol. 73:6582–6589
   PubMedGoogle Scholar
• Lisowska-Grospierre, B., Fondaneche, M. C., Rols, M. P., Griscelli, C., and Fischer, A.. 1994. Two complementation groups account for most cases of inherited MHC class II deficiency. Hum. Mol. Genet. 3:953–958
   PubMedGoogle Scholar
• Lu, H. T., Riley, J. L., Babcock, G. T., Huston, M., Stark, G. R., Boss, J. M., and Ransohoff, R. M.. 1995. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J. Exp. Med. 182:1517–1525
   PubMed Web of Science ®Google Scholar
• Lu, Y., Boss, J. M., Hu, S. X., Xu, H. J., and Blanck, G.. 1996. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. J. Immunol. 156:2495–2502
   PubMed Web of Science ®Google Scholar
• Lu, Y., Tschickardt, M. E., Schmidt, B. J., and Blanck, G.. 1997. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol. Cell Biol. 75:325–332
   PubMedGoogle Scholar
• Lu, Y., Ussery, G. D., Muncaster, M. M., Gallie, B. L., and Blanck, G.. 1994. Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene 9:1015–1019
   PubMed Web of Science ®Google Scholar
• MacDermott, R. P.. 1996. Alterations of the mucosal immune system in inflammatory bowel disease. J. Gastroenterol. 31:907–916
   PubMed Web of Science ®Google Scholar
• Mach, B., Steimle, V., Martinez-Soria, E., and Reith, W.. 1996. Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol. 14:301–331
   PubMed Web of Science ®Google Scholar
• Mahanta, S. K., Scholl, T., Yang, F. C., and Strominger, J. L.. 1997. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Proc. Natl. Acad. Sci. USA 94:6324–6329
   PubMedGoogle Scholar
• Maity, S. N., Sinha, S., Ruteshouser, E. C., and de Crombrugghe, B.. 1992. Three different polypeptides are necessary for DNA binding of mammalian heteromeric CCAAT binding factor. J. Biol. Chem. 267:16574–16580
   PubMedGoogle Scholar
• Mantovani, R.. 1999. The molecular biology of the CCAAT-binding factor NF-Y. Gene 239:15–27
   PubMed Web of Science ®Google Scholar
• Mantovani, R., Pessara, U., Tronche, F., Li, X. Y., Knapp, A. M., Pasquali, J. L., Benoist, C., and Mathis, D.. 1992. Monoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription. EMBO J. 11:3315–3322
   PubMedGoogle Scholar
• Martin, B. K., Chin, K.-C., Skinner, C. A., Olsen, J. C., Dey, A., Ozato, K., and Ting, J. P.-Y.. 1997. Induction of MHC class I expression by the MHC class II transactivator (CIITA). Immunity 6:591–600
   PubMedGoogle Scholar
• Martin, B. K., Frelinger, J. G., and Ting, J. P.. 1999. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J. Immunol. 162:6663–6670
   PubMedGoogle Scholar
• Masternak, K., Barras, E., Zufferey, M., Conrad, B., Corthals, G., Aebersold, R., Sanchez, J. C., Hochstrasser, D. F., Mach, B., and Reith, W.. 1998. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat. Genet. 20:273–277
   PubMedGoogle Scholar
• Masternak, K., Muhlethaler-Mottet A., Villard J., Peretti M., and Reith W.. Molecular genetics of the bare lymphocyte syndrome. Rev. Immunogenet., in press.
   Google Scholar
• Masternak, K., Muhlethaler-Mottet, A., Villard, J., Zufferey, M., Steimle, V., and Reith, W.. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14:1156–1166
   PubMed Web of Science ®Google Scholar
• McDevitt, H. O.. 1998. The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr. Opin. Immunol. 10:677–681
   PubMed Web of Science ®Google Scholar
• Mermod, N., O'Neill, E. A., Kelly, T. J., and Tjian, R.. 1989. The proline-rich transcriptional activator of CTF/NF-I is distinct from the replication and DNA binding domain. Cell 58:741–753
   PubMed Web of Science ®Google Scholar
• Miller, D. M., Rahill, B. M., Boss, J. M., Lairmore, M. D., Durbin, J. E., Waldman, J. W., and Sedmak, D. D.. 1998. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187:675–683
   PubMed Web of Science ®Google Scholar
• Mitchell, P. J., and Tjian, R.. 1989. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 245:371–378
   PubMed Web of Science ®Google Scholar
• Montani, V., Taniguchi, S. I., Shong, M., Suzuki, K., Ohmori, M., Giuliani, C., Napolitano, G., Saji, M., Fiorentino, B., Reimold, A. M., Ting, J. P., Kohn, L. D., and Singer, D. S.. 1998. Major histocompatibility class II HLA-DR alpha gene expression in thyrocytes: counter regulation by class II transactivator and the thyroid Y box protein. Endocrinology 139:280–289
   PubMedGoogle Scholar
• Mora, C., Wong, F. S., Chang, C. H., and Flavell, R. A.. 1999. Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: studies using NOD/CIITA-deficient mice. J. Immunol. 162:4576–4588
   PubMed Web of Science ®Google Scholar
• Moreno, C. S., Beresford, G. W., Louis-Plence, P., Morris, A. C., and Boss, J. M.. 1999. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 10:143–151
   PubMedGoogle Scholar
• Moreno, C. S., Emery, P., West, J. E., Durand, B., Reith, W., Mach, B., and Boss, J. M.. 1995. Purified X2BP cooperatively binds class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome. J. Immunol. 155:4313–4321
   PubMedGoogle Scholar
• Morris, A. C., Riley, J. L., Fleming, W. H., and Boss, J. M.. 1998. MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression. Am. J. Reprod. Immunol. 40:385–394
   PubMedGoogle Scholar
• Muhlethaler-Mottet, A., Otten, L. A., Steimle, V., and Mach, B.. 1997. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16:2851–2860
   PubMed Web of Science ®Google Scholar
• Nagarajan, U. M., Louis-Plence, P., DeSandro, A., Nilsen, R., Bushey, A., and Boss, J. M.. 1999. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 10:153–162 (Erratum, 10:399.)
   PubMedGoogle Scholar
• Nandan, D., and Reiner, N. E.. 1997. TGF-beta attenuates class II transactivator and reveals an accessory pathway of IFN-gamma action. J. Immunol. 158:1095–1101
   PubMed Web of Science ®Google Scholar
• Navarrete Santos, A., Kehlen, A., Schutte, W., Langner, J., and Riemann, D.. 1998. Regulation by transforming growth factor-beta1 of class II mRNA and protein expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int. Immunol. 10:601–607
   PubMedGoogle Scholar
• Nepom, G. T., and Erlich, H.. 1991. MHC class II molecules and autoimmunity. Annu. Rev. Immunol. 9:493–525
   PubMed Web of Science ®Google Scholar
• Nikcevich, K. M., Piskurich, J. F., Hellendall, R. P., Wang, Y., and Ting, J. P.. 1999. Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha. J. Neuroimmunol. 99:195–204
   PubMedGoogle Scholar
• O'Keefe, G. M., Nguyen, V. T., and Benveniste, E. N.. 1999. Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10. Eur. J. Immunol. 29:1275–1285
   PubMed Web of Science ®Google Scholar
• Osborne, A., Tschickardt, M., and Blanck, G.. 1997. Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Res. 25:5095–5102
   PubMedGoogle Scholar
• Ostrand-Rosenberg, S., Clements, V. K., Thakur, A., and Cole, G. A.. 1989. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection. J. Immunogenet. (Oxford) 16:343–349
   PubMedGoogle Scholar
• Ostrand-Rosenberg, S., Thakur, A., and Clements, V.. 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144:4068–4071
   PubMed Web of Science ®Google Scholar
• Otten, L. A., Steimle, V., Bontron, S., and Mach, B.. 1998. Quantitative control of MHC class II expression by the transactivator CIITA. Eur. J. Immunol. 28:473–478
   PubMedGoogle Scholar
• Panelli, M. C., Wang, E., Shen, S., Schluter, S. F., Bernstein, R. M., Hersh, E. M., Stopeck, A., Gangavalli, R., Barber, J., Jolly, D., and Akporiaye, E. T.. 1996. Interferon (IFN)-gamma gene transfer of an EMT6 tumor that is poorly responsive to IFN-gamma stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC. Cancer Immunol. Immunother. 42:99–107
   PubMed Web of Science ®Google Scholar
• Papageorgiou, A. C., Shapiro, R., and Acharya, K. R.. 1997. Molecular recognition of human angiogenin by placental ribonuclease inhibitor—an X-ray crystallographic study at 2.0 A resolution. EMBO J. 16:5162–5177
   PubMed Web of Science ®Google Scholar
• Pieters, J.. 1997. MHC class II restricted antigen presentation. Curr. Opin. Immunol. 9:89–96
   PubMedGoogle Scholar
• Piskurich, J. F., Linhoff, M. W., Wang, Y., and Ting, J. P.. 1999. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor β. Mol. Cell. Biol. 19:431–440
   PubMedGoogle Scholar
• Piskurich, J. F., Wang, Y., Linhoff, M. W., White, L. C., and Ting, J. P.. 1998. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of class II transactivator gene. J. Immunol. 160:233–240
   PubMedGoogle Scholar
• Quan, V., Towey, M., Sacks, S., and Kelly, A. P.. 1999. Absence of MHC class II gene expression in a patient with a single amino acid substitution in class II transactivator protein CIITA. Immunogen 49:957–963
   PubMedGoogle Scholar
• Ramassar, V., Goes, N., Hobart, M., and Halloran, P. F.. 1996. Evidence for the in vivo role of class II transactivator in basal and IFN-gamma induced class II expression in mouse tissue. Transplantation 62:1901–1907
   PubMedGoogle Scholar
• Riegert, P., Andersen, R., Bumstead, N., Dohring, C., Dominguez-Steglich, M., Engberg, J., Salomonsen, J., Schmid, M., Schwager, J., Skjodt, K., and Kaufman, J.. 1996. The chicken beta 2-microglobulin gene is located on a non-major histocompatibility complex microchromosome: a small, G+C-rich gene with X and Y boxes in the promoter. Proc. Natl. Acad. Sci. USA 93:1243–1248
   PubMedGoogle Scholar
• Rigaud, G., Barbaro, A. D., Nicolis, M., Cestari, T., Ramarli, D., Riviera, A.-P., and Accolla, R. S.. 1996. Induction of CIITA and modification of in vivo HLA-DRA promoter occupancy in normal thymic epithelial cells treated with IFN-gamma. J. Immunol. 156:4254–4258
   PubMed Web of Science ®Google Scholar
• Riley, J. L., Westerheide, S. D., Price, J. A., Brown, J. A., and Boss, J. M.. 1995. Activation of class II MHC genes requires both the X box region and class II transactivator (CIITA). Immunity 2:533–543
   PubMedGoogle Scholar
• Rohn, W., Tang, L. P., Dong, Y., and Benveniste, E. N.. 1999. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of class II transactivator gene. J. Immunol. 162:886–896
   PubMed Web of Science ®Google Scholar
• Saifuddin, M., Roebuck, K. A., Chang, C. H., Ting, J. P. Y., and Spear, G. T.. 2000. Cutting edge: activation of HIV-1 transcription by the MHC class II transactivator. J. Immunol. 164:3941–3945
   PubMedGoogle Scholar
• Sartoris, S., Tosi, G., De Lerma Barbaro, A., Cestari, T., and Accolla, R. S.. 1996. Active suppression of class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells. Eur. J. Immunol. 26:2456–2460
   PubMedGoogle Scholar
• Sartoris, S., Valle, M. T., Barbaro, A. L., Tosi, G., Cestari, T., D'Agostino, A., Megiovanni, A. M., Manca, F., and Accolla, R. S.. 1998. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity. J. Immunol. 161:814–820
   PubMed Web of Science ®Google Scholar
• Scholl, T., Mahanta, S. K., and Strominger, J. L.. 1997. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc. Natl. Acad. Sci. USA 94:6330–6334
   PubMedGoogle Scholar
• Seidl, C., Saraiya, C., Osterweil, Z., Fu, Y. P., and Lee, J. S.. 1992. Genetic complexity of regulatory mutants defective for HLA class II gene expression. J. Immunol. 148:1576–1584
   PubMedGoogle Scholar
• Shani, M., Faerman, A., Emerson, C. P., Pearson-White, S., Dekel, I., and Magal, Y.. 1992. The consequences of a constitutive expression of MyoD1 in ES cells and mouse embryos. Symp. Soc. Exp. Biol. 46:19–36
   PubMedGoogle Scholar
• Silacci, P., Mottet, A., Steimle, V., Reith, W., and Mach, B.. 1994. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J. Exp. Med. 180:1329–1336
   PubMed Web of Science ®Google Scholar
• Sims, T. N., Goes, N. B., Ramassar, V., Urmson, J., and Halloran, P. F.. 1997. In vivo class II transactivator expression in mice is induced by a non-interferon-gamma mechanism in response to local injury. Transplantation 64:1657–1664
   PubMedGoogle Scholar
• Sims, T. N., and Halloran, P. F.. 1999. MHC class II regulation in vivo in the mouse kidney. Microbes Infect. 1:903–912
   PubMedGoogle Scholar
• Steimle, V., Durand, B., Barras, E., Zufferey, M., Hadam, M. R., Mach, B., and Reith, W.. 1995. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1021–1032
   PubMedGoogle Scholar
• Steimle, V., Otten, L. A., Zufferey, M., and Mach, B.. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135–146
   PubMed Web of Science ®Google Scholar
• Steimle, V., Siegrist, C. A., Mottet, A., Lisowska-Grospierre, B., and Mach, B.. 1994. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265:106–109
   PubMed Web of Science ®Google Scholar
• Sugawara, M., Scholl, T., Ponath, P. D., and Strominger, J. L.. 1994. A factor that regulates class II major histocompatibility complex gene DPA is a member of a subfamily of zinc finger proteins that includes a Drosophila developmental control protein. Mol. Cell. Biol. 14:8438–8450
   PubMedGoogle Scholar
• Sultmann, H., Mayer, W. E., Figueroa, F., O'Huigin, C., and Klein, J.. 1994. Organization of MHC class II B genes in the zebrafish (Brachydanio rerio). Genomics 23:1–14
   PubMedGoogle Scholar
• Tai, A. K., Zhou, G., Chau, K., and Ono, S. J.. 1999. Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription. Mol. Immunol. 36:447–460
   PubMed Web of Science ®Google Scholar
• Tanaka, M., and Herr, W.. 1990. Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell 60:375
   PubMedGoogle Scholar
• Taneja, V., and David, C. S.. 1999. HLA class II transgenic mice as models of human diseases. Immunol. Rev. 169:67–79
   PubMed Web of Science ®Google Scholar
• Taxman, D. J., Cressman D. E., and Ting J. P. Y.. Identification of CIITA-regulated genes by representational difference analysis: discoordinate regulation of the DN/DO heterdodimer. J. Immunol., in press.
   Google Scholar
• Ting, J. P.-Y., Wright, K. L., Chin, K.-C., Brickey, W. J., and Li, G.. 1997. The DMB promoter: delineation, in vivo footprint, trans-activation and transdominant-suppression. J. Immunol. 159:5457–5462
   PubMedGoogle Scholar
• Ting, J. P.-Y., and Zhu, X. S.. 1999. Class II MHC genes: a model gene regulatory system with great biologic consequences. Microbes Infect. 1:855–861
   PubMed Web of Science ®Google Scholar
• Tosi, G., De Lerma Barbaro, A., D'Agostino, A., Valle, M. T., Megiovanni, A. M., Manca, F., Caputo, A., Barbanti-Brodano, G., and Accolla, R. S.. 2000. HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines. Eur. J. Immunol. 30:19–28
   PubMedGoogle Scholar
• Tschickardt, M. E., Lu, Y., Jacim, M., Ussery, G. D., Steimle, V., Mach, B., and Blanck, G.. 1995. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines. Int. J. Cancer 62:461–465
   PubMedGoogle Scholar
• Vilen, B. J., Cogswell, J. P., and Ting, J. P.. 1991. Stereospecific alignment of the X and Y elements is required for major histocompatibility complex class II DRA promoter function. Mol. Cell. Biol. 11:2406–2415
   PubMedGoogle Scholar
• Vilen, B. J., Penta, J. F., and Ting, J. P.-Y.. 1992. Structural constraints within a trimeric transcriptional regulatory region: constitutive and interferon-gamma inducible expression of the HLA-DRA gene. J. Biol. Chem. 267:23728–23734
   PubMedGoogle Scholar
• Villard, J., Muhlethaler-Mottet, A., Bontron, S., Mach, B., and Reith, W.. 1999. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes. Int. Immunol. 11:461–469
   PubMedGoogle Scholar
• Villard, J., Peretti, M., Masternak, K., Barras, E., Caretti, G., Mantovani, R., and Reith, W.. 2000. A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y. Mol. Cell. Biol. 20:3364–3376
   PubMedGoogle Scholar
• Weetman, A. P.. 1999. The immunology of pregnancy. Thyroid 9:643–646
   PubMed Web of Science ®Google Scholar
• Weintraub, H.. 1993. The MyoD family and myogenesis: redundancy, networks, and thresholds. Cell 75:1241–1244
   PubMed Web of Science ®Google Scholar
• Weintraub, H., Davis, R., Tapscott, S., Thayer, M., Krause, M., Benezra, R., Blackwell, T. K., Turner, D., Rupp, R., and Hollenberg, S.. 1991. The myoD gene family: nodal point during specification of the muscle cell lineage. Science 251:761–766
   PubMed Web of Science ®Google Scholar
• Westerheide, S. D., Louis-Plence, P., Ping, D., He, X. F., and Boss, J. M.. 1997. HLA-DMA and HLA-DMB gene expression functions through the conserved S-X-Y region. J. Immunol. 158:4812–4821
   PubMedGoogle Scholar
• Weyand, C. M., and Goronzy, J. J.. 1999. HLA polymorphisms and T cells in rheumatoid arthritis. Int. Rev. Immunol. 18:37–59
   PubMedGoogle Scholar
• Williams, G. S., Malin, M., Vremec, D., Chang, C. H., Boyd, R., Benoist, C., and Mathis, D.. 1998. Mice lacking the transcription factor CIITA—a second look. Int. Immunol. 10:1957–1967
   PubMedGoogle Scholar
• Wojciechowski, W., DeSanctis, J., Skamene, E., and Radzioch, D.. 1999. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guerin involves class II transactivator and depends on the Nramp1 gene. J. Immunol. 163:2688–2696
   PubMedGoogle Scholar
• Wright, K. L., Chin, K. C., Linhoff, M., Skinner, C., Brown, J. A., Boss, J. M., Stark, G. R., and Ting, J. P.. 1998. CIITA stimulation of transcription factor binding to major histocompatibility complex class II and associated promoters in vivo. Proc. Natl. Acad. Sci. USA 95:6267–6272
   PubMedGoogle Scholar
• Wright, K. L., White, L. C., Kelly, A., Beck, S., Trowsdale, J., and Ting, J. P.-Y.. 1995. Coordinate regulation of the human TAP1 and LMP2 genes from a shared bi-directional promoter. J. Exp. Med. 181:1459–1471
   PubMed Web of Science ®Google Scholar
• Wu, Z., Biro, P. A., Mirakian, R., Hammond, L., Curcio, F., Ambesi-Impiombato, F. S., and Bottazzo, G. F.. 1999. HLA-DMB expression by thyrocytes: indication of the antigen-processing and possible presenting capability of thyroid cells. Clin. Exp. Immunol. 116:62–69
   PubMedGoogle Scholar
• Yazawa, T., Kamma, H., Fujiwara, M., Matsui, M., Horiguchi, H., Satoh, H., Fujimoto, M., Yokoyama, K., and Ogata, T.. 1999. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J. Pathol. 187:191–199
   PubMed Web of Science ®Google Scholar
• Yun, S., Gustafsson, K., and Fabre, J. W.. 1998. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain. Transplantation 66:103–111
   PubMedGoogle Scholar
• Zeleznik-Le, N. J., Azizkhan, J. C., and Ting, J. P.. 1991. Affinity-purified CCAAT-box-binding protein (YEBP) functionally regulates expression of a human class II major histocompatibility complex gene and the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA 88:1873–1877
   PubMedGoogle Scholar
• Zhong, G., Fan, T., and Liu, L.. 1999. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J. Exp. Med. 189:1931–1938
   PubMedGoogle Scholar
• Zhou, H., and Glimcher, L. H.. 1995. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity 2:545–553
   PubMedGoogle Scholar
• Zhou, H., Su, H. S., Zhang, X., Douhan, J.III, and Glimcher, L. H.. 1997. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant. J. Immunol. 158:4741–4749
   PubMed Web of Science ®Google Scholar
• Zhu, X.-S., Linhoff M. W., Li G., Chin K.-C., Maity S. N. and Ting J. P.-Y.. 2000. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of class II major histocompatibility promoter. 20:6051–6061.
   Google Scholar